🔴 Neumora Therapeutics, Inc. is trading 5.2% down today following Phase 3 trial failures and workforce reductions

Neumora Therapeutics, Inc. is trading 5.2% down at $1.45, extending a sharp sell-off triggered by the failure of its lead depression drug candidate.

• The company discontinued its navacaprant program after the KOASTAL-2 and KOASTAL-3 Phase 3 trials for Major Depressive Disorder (MDD) failed to meet primary endpoints.
• Neumora is cutting approximately 35% of its workforce as part of a broader restructuring to focus on remaining pipeline assets.
• Investors remain focused on the company's ability to navigate restructuring risks and the long-term viability of its remaining clinical programs.